Skin barrier dysfunction plays a key role in atopic dermatitis (AD). This impairment is related to altered composition and metabolism of epidermal sphingolipids and a deficiency of ceramides. Glycosaminoglycans (GAGs), and especially hyaluronic acid, could be useful in the management of AD. This study aimed to evaluate the effects of a novel topical treatment consisting of sphingolipids and GAGs extracts in dogs with AD. This formulation is different from previously tested products because the sphingolipid extract contained high amounts of sphingomyelin, a precursor of ceramides, and this has been shown to enhance endogenous synthesis of ceramides and to increase lamellar-related structures in vitro. Thus, it was hypothesized that this formulation could improve clinical disease and skin barrier function in patients with AD. Twelve house dust mite (HDM) allergic atopic beagle dogs were randomized into two groups: control (n = 6; no treatment) or treatment (n = 6; topical sphingolipids and GAGs twice weekly for 8 weeks). Dogs were challenged with allergen twice weekly and the severity of dermatitis was scored using the canine atopic dermatitis and extent severity index (CADESI-03) once weekly. Skin barrier function (measurement of transepidermal water loss) and severity of pruritus (both pruritus visual analog scale [PVAS] and pruritus timed episodes) were assessed at 0, 4 and 8 weeks of treatment. Assessments were done by personnel unaware of group allocation. Complete blood count, serum biochemistry and stratum corneum (SC) lipidomics analyses were done at baseline and at week 8. Compared to baseline, significant increases in CADESI (P = 0.0003) and PVAS (P = 0.041) were observed only in the control group, and SC polyunsaturated fatty acids increased significantly only with treatment (P = 0.039). Compared to control, treatment group had a significantly lower CADESI after 1 week (P = 0.0078) and a significantly lower PVAS after 8 weeks (P = 0.0448). Treatment was well tolerated. In this study in dogs with AD, a new topical formulation containing sphingomyelin-rich sphingolipids plus GAGs extracts attenuated the clinical worsening induced by HDM, supporting its use in atopic patients, either as an adjunctive treatment or used as monotherapy in certain cases.

中文翻译：

---

SPHINGOLIPIDS和糖基葡聚糖治疗犬特应性皮炎的局部治疗

皮肤屏障功能障碍在特应性皮炎（AD）中起关键作用。这种损害与表皮鞘脂的组成和代谢改变以及神经酰胺缺乏有关。糖胺聚糖（GAGs），尤其是透明质酸，可用于AD的治疗。这项研究旨在评估由鞘脂和GAG提取物组成的新型局部治疗对AD犬的影响。该制剂与先前测试的产品不同，因为鞘脂提取物含有大量的鞘磷脂，即神经酰胺的前体，并且已显示可增强神经酰胺的内源性合成并在体外增加层状相关结构。因此，假设该制剂可以改善AD患者的临床疾病和皮肤屏障功能。将十二只屋尘螨（HDM）过敏性特应性比格犬随机分为两组：对照组（n = 6；未治疗）或治疗（n = 6；局部鞘脂和GAG，每周两次，共8周）。每周两次用过敏原对狗进行攻击，每周一次使用犬异位性皮炎和程度严重性指数（CADESI-03）对皮炎的严重性进行评分。在治疗第0、4和8周时评估皮肤屏障功能（测量表皮失水量）和瘙痒严重程度（视觉瘙痒模拟量表[PVAS]和瘙痒定时发作）。评估是由不知道小组分配的人员进行的。在基线和第8周进行了全血细胞计数，血清生化和角质层（SC）脂质组学分析。与基线相比，CADESI（P = 0.0003）和PVAS（P = 0）显着增加。041）仅在对照组中观察到，SC多不饱和脂肪酸仅在治疗后显着增加（P = 0.039）。与对照组相比，治疗组在1周后CADESI显着降低（P = 0.0078），在8周后PVAS显着降低（P = 0.0448）。治疗耐受性良好。在这项针对AD犬的研究中，一种新的局部用药配方包含富含鞘磷脂的鞘脂和GAGs提取物，可减轻HDM引起的临床恶化，支持其在特应性患者中的使用，在某些情况下可作为辅助治疗或单药治疗。0078），且8周后的PVAS显着降低（P = 0.0448）。治疗耐受性良好。在这项针对AD犬的研究中，一种新的局部用药配方包含富含鞘磷脂的鞘脂和GAGs提取物，可减轻HDM引起的临床恶化，支持将其用于特应性患者，在某些情况下可作为辅助治疗或单药治疗。0078），且8周后的PVAS显着降低（P = 0.0448）。治疗耐受性良好。在这项针对AD犬的研究中，一种新的局部用药配方包含富含鞘磷脂的鞘脂和GAGs提取物，可减轻HDM引起的临床恶化，支持将其用于特应性患者，在某些情况下可作为辅助治疗或单药治疗。